{
    "nctId": "NCT00567879",
    "briefTitle": "A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer (MBC) Whose Disease Has Progressed on or After Trastuzumab",
    "officialTitle": "A Phase Ib/IIa Trial of Panobinostat in Combination With Trastuzumab in Adult Female Patients With HER2 Positive Metastatic Breast Cancer Whose Disease Has Progressed During or Following Therapy With Trastuzumab",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 56,
    "primaryOutcomeMeasure": "Number of Participants With Dose Limiting Toxicities (DLTs)",
    "eligibilityCriteria": "Key Inclusion criteria:\n\n* Age \\> 18 year old\n* Confirmed HER2+ ve metastatic breast cancer\n* Prior treatment and progression on trastuzumab\n* Patients must have adequate laboratory values\n* Eastern Cooperative Oncology Group (ECOG) performance status of \\<2\n\nKey Exclusion criteria:\n\n* Patients with active central nervous system (CNS) disease or brain metastases except those who have been previously treated and have been stable for at least 3 months.\n* Impaired heart function or clinically significant heart disease\n* Impairment of gastrointestinal (GI) function, or GI disease that may significantly alter the absorption of LBH589\n* Ongoing diarrhea\n* Liver or renal disease with impaired hepatic or renal functions\n* Concomitant use of any anti-cancer therapy or certain drugs\n* Female patients who are pregnant or breast feeding\n* Patients not willing to use an effective method of birth control",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}